A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8‐week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Epistemonikos ID: f5ae48e61ae880b3d1b8836cb7aadad3a1d41f28
First added on: Jul 25, 2023